What You Should Know About Drug Pricing, The Phase 3 ASAP Leukemia Trial

PW Editorial Board Member Alex McDonald, MD, talks with Hussain Lalani, MD, MPH ( Brigham and Women’s Hospital, Harvard Medical School), who’s research focuses on understanding the challenges and inequities patients face in accessing affordable prescription drugs and evaluating the impact of health policies and interventions. He also serves on the National Steering Committee of Doctors for America’s Drug Affordability Action Team. They talk about what all doctors in the US should know about pharmaceutical pricing, and the implications that process can have.  Also, Matthias Stelljes, MD (University of Muenster, Germany), discusses the outcomes and implications of the ASAP trial, which assessed the management of relapsed or refractory acute myeloid leukemia using intensive chemotherapy in advance of allogeneic hematopoietic cell transplantation.

Let us know what you thought of this week’s episode on Twitter: @physicianswkly

Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!

Thanks for listening!